Pharma

Pharmalot Ed Silverman

STAT Plus: South African regulator decides Vertex provides sufficient access to CF drugs, angering activists

The Readout Meghana Keshavan

STAT Plus: GLP-1 drugs spark disagreements in Trump’s circle

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Editas layoffs, House Republicans probing CVS, and more

Pharma Angus Chen

STAT Plus: For a leukemia that keeps returning, AbbVie drug may offer chance for a deep remission

Pharmalot Ed Silverman

STAT Plus: Tuberculosis R&D funding is up, but still short of goals and dominated by a few players, report finds

Health Tech Newsletter Mario Aguilar

STAT Plus: When AI becomes a tool to fight insurance denials

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about unsupported drug price hikes, an annual HIV prevention shot, and more

The Readout Elaine Chen

STAT Plus: The biotech news you need to read today

Pharma Matthew Herper

STAT Plus: Pfizer’s blockbuster Ibrance slows tumor progression in another type of breast cancer

Pharmalot Ed Silverman

STAT Plus: Prices for 5 drugs were hiked without proof of new benefits, costing the U.S. $815M in 2023, report finds

Pharmalot Ed Silverman

STAT Plus: Wall Street wags say a bill to force insurers or PBMs to sell pharmacies has low odds

Pharma Jason Mast

Gilead to test once-a-year HIV prevention shot

Pharma Elaine Chen and Katie Palmer

STAT Plus: Eli Lilly strikes Zepbound deal with Ro, amid questions about future of compounded GLP-1s

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a bill to force insurers to sell pharmacies, Lilly testing GLP-1 meds for addiction, and more

The Readout Elaine Chen

STAT Plus: Eli Lilly’s new maneuvers in GLP-1 treatment

Biotech STAT Staff, Adam Feuerstein, Angus Chen, and Meghana Keshavan

STAT Plus: An entertaining biotech fight, and a ‘nail in the coffin’ for transplants in mantle cell lymphoma

Pharmalot Ed Silverman

STAT Plus: Ohio court sides with CVS, Walmart, and Walgreens in opioid case

D.C. Diagnosis Sarah Owermohle

STAT Plus: Budget negotiations heat up as ACA subsidy extension, BIOSECURE get dropped

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about pharma not lobbying against RFK Jr., a Supreme Court 340B appeal, and more

The Readout Elaine Chen

STAT Plus: Uniqure gets FDA OK to seek accelerated approval

Health tech Mario Aguilar

STAT Plus: Do GLP-1s work for Parkinson’s? A health tech startup pitches pharma on quick answers

Health Angus Chen, Adam Feuerstein, Jonathan Wosen, and Meghana Keshavan

STAT Plus: Johnson & Johnson seeks first drug approval for treatment of smoldering myeloma

Exclusive Rachel Cohrs Zhang and John Wilkerson

STAT Plus: The pharma industry isn’t lobbying against RFK Jr.’s nomination for a top health role

Health Angus Chen

STAT Plus: Early treatment may delay or prevent multiple myeloma in high-risk patients, according to new study

Pharma Andrew Joseph

STAT Plus: GSK myeloma medicine improves survival in trial, another step in the drug’s revival

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Biosecure Act setback, a judge ordering release of Covid vaccine data, and more

The Readout Meghana Keshavan

STAT Plus: AbbVie drug succeeds in another Parkinson’s trial

Health Adam Feuerstein, Jonathan Wosen, Angus Chen, and Meghana Keshavan

STAT Plus: Biopharma leaders lay out vision for the future of blood cancer treatment